Divi's Laboratories Limited

DIVISLAB

INE361B01024

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 12:43:52 24/05/2024 BST			5-day change	1st Jan Change
4,122 ^INR	+0.23%		+4.92%	+5.60%

05-25	Transcript : Divi's Laboratories Limited, Q4 2024 Earnings Call, May 25, 2024
05-25	Divi's Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Divi's Laboratories Limited Appoints S. Ganapaty as Independent Additional Director

July 22, 2017 at 10:59 am

Divi's Laboratories Limited at its board meeting held on July 22, 2017, approved the appointment of Dr. S. Ganapaty as Independent Additional Director effective from July 22, 2017.

Latest news about Divi's Laboratories Limited

Transcript : Divi's Laboratories Limited, Q4 2024 Earnings Call, May 25, 2024	05-25
Divi's Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-25	CI
Divi's Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-25	CI
Divi's Laboratories Limited Recommends A Final Dividend for the Financial Year 2023-24	05-25	CI
Weak March Quarter Earnings Weigh Down Indian Equities on Friday	04-26	MT
Divi's Laboratories Plans Up To INR7 Billion Investment to Boost Capacity	04-25	MT
Indian Equities Close Higher on Friday, Led by Metal, Banking Stocks	04-19	MT
Indian Equities Close Lower on Friday As Hopes for US Rate Cute in June Fade	04-12	MT
Indian Equities End Higher on Wednesday, Lifted Mainly by Metal Stocks	04-10	MT
Divi's Laboratories Limited Approves Appointment of Dr. S. Devendra Rao as Whole-Time Director (Manufacturing)	04-05	CI
Indian Equities Close with Marginal Loss on Wednesday as Traders Scale Down Hopes on US Rate Cuts	04-03	MT
Indian Equities End Higher on Monday, Led by Gains in Metal, Realty Stocks	04-01	MT
Indian Equities Close Lower on Monday, Draagged by Major Banking, Financial Companies	02-12	MT
INDIA STOCKS-Energy shares drag India's blue-chip stocks; small, mid-caps slide	02-12	RE
Transcript : Divi's Laboratories Limited, Q3 2024 Earnings Call, Feb 10, 2024	02-10
Divi's Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-10	CI
Indian Equities Break Five-Day Winning Streak on Tuesday, Dragged by Realty, IT Stocks	01-16	MT
INDIA STOCKS-Indian shares decline amid selling pressure in financials, IT	01-02	RE
Indian Equities End Higher for Third Straight Day on Tuesday, Lifted by US Inflation Drop	12-26	MT
Indian Equities End Higher Midweek, Led by Gains in Bank, Auto and IT Stocks	11-29	MT
Selling in IT Drags Indian Equities to Close Lower on Friday	11-24	MT
INDIA STOCKS-Indian shares lacklustre as IT stocks snap rally	11-24	RE
Profit Booking Amid Weak Global Cues Drags Indian Equities to End Flat on Tuesday	11-07	MT
Jefferies Downgrades Divi’s Laboratories to Hold From Buy, Adjusts Price Target to INR3,510 From INR4,300	11-07	MT
Divi's Laboratories' Consolidated Profit Slides in Fiscal Q2; EPS, Revenue Miss Estimates	11-07	MT

Chart Divi's Laboratories Limited

Duration

Period

More charts

Divi's Laboratories Limited is specialized in the development and manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Net sales by source of revenue break down into product sales (97.9%) and service sales (2.1%). At the end of March 2020, the group has 2 production sites located in India.

Sector

Pharmaceuticals

Calendar

11/08/2024 - Q1 2025 Earnings Release (Projected)

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Divi's Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4,122 INR

Average target price

3,511 INR

Spread / Average Target

-14.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DIVI'S LABORATORIES LIMITED	+5.60%	13.18B
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals